REVB vs. ARDS, ARAV, NBY, BPTS, PHIO, BPTSY, LGVN, MBIO, NTBL, and AGRX
Should you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Aridis Pharmaceuticals (ARDS), Aravive (ARAV), NovaBay Pharmaceuticals (NBY), Biophytis (BPTS), Phio Pharmaceuticals (PHIO), Biophytis (BPTSY), Longeveron (LGVN), Mustang Bio (MBIO), Notable Labs (NTBL), and Agile Therapeutics (AGRX). These companies are all part of the "pharmaceutical preparations" industry.
Aridis Pharmaceuticals (NASDAQ:ARDS) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk.
In the previous week, Revelation Biosciences had 7 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 7 mentions for Revelation Biosciences and 0 mentions for Aridis Pharmaceuticals. Aridis Pharmaceuticals' average media sentiment score of 1.19 beat Revelation Biosciences' score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the news media.
Revelation Biosciences has a net margin of 0.00% compared to Revelation Biosciences' net margin of -5.11%. Revelation Biosciences' return on equity of 0.00% beat Aridis Pharmaceuticals' return on equity.
Revelation Biosciences has lower revenue, but higher earnings than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.
Aridis Pharmaceuticals received 92 more outperform votes than Revelation Biosciences when rated by MarketBeat users. However, 63.83% of users gave Revelation Biosciences an outperform vote while only 61.00% of users gave Aridis Pharmaceuticals an outperform vote.
Aridis Pharmaceuticals currently has a consensus target price of $2.00, indicating a potential upside of 3,125.81%. Given Revelation Biosciences' higher possible upside, research analysts plainly believe Aridis Pharmaceuticals is more favorable than Revelation Biosciences.
Aridis Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
9.7% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Revelation Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Aridis Pharmaceuticals beats Revelation Biosciences on 9 of the 16 factors compared between the two stocks.
Get Revelation Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revelation Biosciences Competitors List
Related Companies and Tools
